The use of insulin analogues in pregnancy
Excellent glycaemic control is essential in pregnancy to optimise maternal and foetal outcomes. The aim of this review is to assess the efficacy and safety of insulin analogues in pregnancy. Insulin lispro and insulin aspart are safe in pregnancy and may improve post‐prandial glycaemic control in women with type 1 diabetes. However, a lack of data indicating improved foetal outcomes would suggest that there is no imperative to switch to a short‐acting analogue where the woman's diabetes is well controlled with human insulin. There are no reports of the use of insulin glulisine in pregnancy and so its use cannot be reco...
Source: Diabetes, Obesity and Metabolism - April 9, 2013 Category: Endocrinology Authors: K. Lambert, R. I. G. Holt Tags: REVIEW ARTICLE Source Type: research
A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review
The aim of this review is to summarize the clinical efficacy, tolerability and safety data of insulin detemir, and compare its use with that of neutral protamine Hagedorn insulin in randomized controlled trials in people with type 1 or type 2 diabetes. A literature search was conducted with PubMed using predefined search terms. Studies were included if they met the following criteria: randomized, controlled trial; comparison of insulin detemir with NPH insulin; non‐hospitalized adults aged ≥18 years with either type 1 or type 2 diabetes; and study duration of ≥12 weeks. The following types of studies were excluded: n...
Source: Diabetes, Obesity and Metabolism - April 3, 2013 Category: Endocrinology Authors: B. M. Frier, D. Russell‐Jones, T. Heise Tags: Unsolicited Review Article Source Type: research
A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes
Abstract
This 26‐wk observational study in children and adolescents with type 1 diabetes (T1D) in Sweden investigated the safety and efficacy of insulin detemir (IDet) in newly diagnosed (ND) patients and those with established diabetes (ED) switching to IDet. A total of 159 patients initiated IDet as part of basal–bolus therapy, 59 in the ND stratum (mean age 9.7 yr) and 97 in the ED stratum (mean age 12.5 yr). The primary outcome measure was the incidence of severe adverse drug reactions; just one major hypoglycemic event occurred in a patient in the ND stratum during the study and one patient was withdrawn due to ...
Source: Pediatric Diabetes - March 1, 2013 Category: Endocrinology Authors: Annelie Carlsson, Gun Forsander, Johnny Ludvigsson, Sara Larsen, Eva Örtqvist, Tags: Original Article Source Type: research
Once‐daily initiation of basal insulin as add‐on to metformin: a 26‐week, randomized, treat‐to‐target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
ConclusionWhile both detemir and glargine, when added to metformin therapy, improved glycaemic control, glargine resulted in greater reductions in HbA1c, while detemir demonstrated less weight gain and hypoglycaemia. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - February 19, 2013 Category: Endocrinology Authors: L. Meneghini, J. Kesavadev, M. Demissie, A. Nazeri, P. Hollander Tags: Original Paper Source Type: research
The A1chieve study – an observational non‐interventional study of patients with type 2 diabetes mellitus initiating or switched to insulin analogue therapy: subgroup analysis of the Gulf population
Conclusions: Initiating or switching to insulin analogues was well tolerated and resulted in significant improvements in glycaemic control in T2DM patients in the Gulf. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - January 11, 2013 Category: Internal Medicine Authors: N. El‐Naggar, A. Almansari, K. Khudada, S. Salman, N. Mariswamy, W. AbdelFattah, F. Hashim Tags: ORIGINAL PAPER Source Type: research
Metabolic control by insulin detemir in basal‐bolus therapy: treat‐to‐target study in children and adolescents with type 1 diabetes
ConclusionSince twice‐daily determir showed no clinical advantage over once‐daily detemir, it appears reasonable to commence all children on once‐daily detemir, taking into consideration that younger children and those in active puberty may require twice‐daily therapy (ClinicalTrials.gov number, NCT00542399). (Source: Pediatric Diabetes)
Source: Pediatric Diabetes - January 4, 2013 Category: Endocrinology Authors: Revital Nimri, Yael Lebenthal, Shlomit Shalitin, Hadasa Benzaquen, Sharon Demol, Moshe Phillip Tags: Original Article Source Type: research
Metabolic control of insulin detemir in basal‐bolus therapy: treat‐to‐target study in children and adolescents with type 1 diabetes†
ConclusionSince twice‐daily determir showed no clinical advantage over once‐daily detemir, it appears reasonable to commence all children on once‐daily detemir, taking into consideration that younger children and those in active puberty may require twice‐daily therapy (ClinicalTrials.gov number, NCT00542399). (Source: Pediatric Diabetes)
Source: Pediatric Diabetes - January 4, 2013 Category: Endocrinology Authors: Revital Nimri, Yael Lebenthal, Shlomit Shalitin, Hadasa Benzaquen, Sharon Demol, Moshe Phillip Tags: Original Article Source Type: research
In response to Pantalone et al. Use of insulin detemir and insulin glargine during pregnancy: Are the Data convincing?
Endocrine Practice, Ahead of Print. (Source: Endocrine Practice)
Source: Endocrine Practice - May 1, 2012 Category: Endocrinology Authors: Alan Moses Source Type: research
